FREQUENTLY ASKED QUESTIONS
Common Questions About GHRH Research Peptides
Answers drawn from the published literature — cited, not speculated.
What is sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide that replicates the amino-terminal fragment of the body's own growth hormone-releasing hormone (GHRH). It is the shortest GHRH fragment that retains full activity at the pituitary GHRH receptor. It was once FDA-approved for pediatric GH deficiency, commercially withdrawn in 2008, and is now available through compounding pharmacies as a Category 1 bulk substance. It is prohibited in sport under WADA rules [1][4].
What does sermorelin do to the body?
Sermorelin binds GHRH receptors on pituitary somatotrophs and activates a signaling cascade — cAMP/PKA — that stimulates the pituitary to synthesize and release its own growth hormone in pulses [1]. GH then drives IGF-1 production in the liver. Because the signal comes from upstream, the normal feedback system (somatostatin, IGF-1 suppression) remains intact, preserving the pulsatile rhythm of GH secretion. In older men, twice-daily dosing reversed age-related decreases in GH and IGF-1 in a 14-day study [7].
Does sermorelin work?
For stimulating GH release in the laboratory sense, yes — controlled studies confirm dose-dependent GH and IGF-1 elevation [6][7]. For the clinical outcomes most people currently seek (body composition improvement, anti-aging, vitality in healthy adults), the evidence is far thinner. A prominent Annals of Internal Medicine editorial judged GH-secretagogue use for aging 'not yet ready for prime time' [3]. Pediatric GH deficiency is the indication with the strongest historical evidence [5].
How long does it take for sermorelin to work?
Community reports consistently describe a slow buildup: the first month often feels uneventful, with sleep and energy changes sometimes only appearing in the second or third month. This timing is not from a controlled trial — it is an anecdotal pattern from research-use communities and wellness-clinic summaries. These are anecdotal reports, not clinical evidence. There is no published controlled trial establishing a specific onset timeline for adult wellness outcomes.
What is CJC-1295?
CJC-1295 is a tetrasubstituted synthetic analog of human growth hormone-releasing factor (hGRF(1-29)). Four amino-acid substitutions make it resistant to enzymatic degradation, extending its half-life far beyond natural GHRH. The DAC variant adds covalent albumin binding, pushing the estimated half-life to 5.8–8.1 days [10]. It has never been approved for human use anywhere and was reviewed — and not recommended — for the FDA's 503A compounding bulks list in 2024. It is banned in sport at all times [8].
What does CJC-1295 do?
Like sermorelin and tesamorelin, CJC-1295 binds the GHRH receptor and stimulates pulsatile GH release from the pituitary, raising circulating IGF-1. What distinguishes it is duration: in healthy adults, a single dose raised mean plasma GH for six days or more and IGF-1 for 9-11 days, with multiple doses keeping IGF-1 above baseline for up to 28 days [10]. Pulsatile GH secretion was preserved during continuous stimulation in a separate study [11]. No controlled trial has established clinical outcomes for this sustained GH/IGF-1 elevation.
Is CJC-1295 safe?
An honest answer to this question requires acknowledging what is unknown. The compound has never been approved, its development program was discontinued, and long-term human safety data do not exist. The FDA's 2024 PCAC cited immunogenicity and other safety concerns. Theoretical risks include sustained IGF-1 elevation (oncologic concern), fluid retention and nerve compression, and insulin sensitivity effects — all mechanism-based concerns [1][10]. The DAC form carries higher exposure than the no-DAC form. Anyone interpreting this compound should treat it as investigational with an unresolved safety profile.
How much CJC-1295 should I take?
This desk does not provide dosing information. CJC-1295 has no approved human indication, no regulatory-agency-sanctioned dose, and no evidence base in healthy adults beyond early pharmacokinetic studies. This site covers research peptides as a literature digest only — not as a source of treatment recommendations. No content here should be read as medical advice.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human GHRH, modified at the N-terminus with a trans-3-hexenoyl group that blocks DPP-IV cleavage and extends plasma stability. Unlike the other compounds on this desk, it has received FDA approval — specifically for reducing excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy (NDA 022505, 2010) [13]. All other uses are off-label. It is also prohibited in sport under WADA S2.
What does tesamorelin do?
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotrophs, stimulating pulsatile GH release and downstream IGF-1 production. GH promotes preferential lipolysis — breakdown of stored fat — in visceral adipose tissue, and also reduces hepatic fat [1][13][14]. In HIV-lipodystrophy trials, these effects have been measured and replicated across multiple randomized controlled studies. The fat-reduction effect reverses when the compound is discontinued [16].
How does tesamorelin work?
The mechanism is upstream stimulation of the body's own GH secretion: tesamorelin activates the Gs/adenylyl-cyclase/cAMP/PKA pathway in pituitary somatotrophs, which synthesize and release GH in pulses. GH drives IGF-1 in the liver. In a study of healthy men, two weeks of daily tesamorelin significantly raised IGF-1 by 181 micrograms/liter (P<0.0001) without significantly affecting fasting glucose or insulin sensitivity [15]. The N-terminal modification is what makes it more stable than native GHRH in plasma.
Will tesamorelin help me lose belly fat?
This question depends entirely on context. In adults with HIV-associated lipodystrophy — the approved indication — the evidence says yes: multiple randomized trials show statistically and clinically meaningful visceral fat reduction [12][14][16]. For people without HIV lipodystrophy seeking general fat loss, there is no large Phase 3 trial evidence. Some GHRH-analog research in aging populations shows favorable body-composition effects [2], but those findings were from GHRH analogs in cognitive-impairment and aging contexts, and tesamorelin for general fat loss in non-HIV adults is off-label. This desk does not recommend treatments.